logo-loader
viewImugene Ltd

Imugene begins manufacture of its innovative cancer vaccine for trials

KEY-Vaxx has shown potential in preclinical studies, outperforming an industry-standard antibody.

keyboard
Imugene has filed a new provisional patent in Australia

Imugene Limited (ASX:IMU) has formally commenced cGMP (current good manufacturing practice) manufacture of the clinical batch of its cancer vaccine KEY-Vaxx.

The cGMP batch is part of the pre-clinical development for the proposed PD-1 phase I clinical trial to be conducted in 2019.

AmbioPharm Inc, a US-based peptide manufacturing company has been appointed to manufacture the vaccine.

KEY-Vaxx is a B-cell peptide cancer vaccine which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and potentially produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers.

KEY-Vaxx has shown potential in preclinical studies, outperforming an industry-standard antibody in a mouse model of HER2+ colorectal cancer.

New provisional patent

The protection of Imugene’s global position in PD-1 B-cell cancer vaccines has been strengthened with the filing of a new provisional patent in Australia titled “A vaccine composition and uses thereof”.

READ: Imugene signs exclusive, world-widelicence for cancer vaccine

Imugene managing director Leslie Chong said: “Maintaining and strengthening our already strong international intellectual property position is a key area of focus in maintaining the competitive advantage of KEY-Vaxx and any future improvements, vaccine formulations and clinical uses.

“We are extremely pleased with the progress made from our expert scientific team.”

Quick facts: Imugene Ltd

Price: 0.022 AUD

ASX:IMU
Market: ASX
Market Cap: $79.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the...

on 8/7/19

2 min read